Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
13.09
-1.36 (-9.41%)
At close: Dec 18, 2024, 4:00 PM
13.00
-0.09 (-0.69%)
Pre-market: Dec 19, 2024, 4:36 AM EST
Wave Life Sciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Cash & Equivalents | 310.95 | 200.35 | 88.5 | 150.56 | 184.5 | 147.16 | Upgrade
|
Cash & Short-Term Investments | 310.95 | 200.35 | 88.5 | 150.56 | 184.5 | 147.16 | Upgrade
|
Cash Growth | 122.20% | 126.39% | -41.22% | -18.39% | 25.37% | -15.82% | Upgrade
|
Accounts Receivable | - | 21.09 | - | - | 30 | 20 | Upgrade
|
Receivables | - | 21.09 | - | - | 30 | 20 | Upgrade
|
Prepaid Expenses | 10.57 | 9.91 | 7.93 | 6.58 | 10.43 | 9.63 | Upgrade
|
Other Current Assets | 3 | 4.02 | 2.11 | 5.42 | 5.11 | 8.69 | Upgrade
|
Total Current Assets | 324.52 | 235.37 | 98.54 | 162.56 | 230.04 | 185.48 | Upgrade
|
Property, Plant & Equipment | 30.05 | 35.72 | 44.13 | 40.64 | 45.43 | 54.47 | Upgrade
|
Long-Term Accounts Receivable | - | - | - | - | - | 30 | Upgrade
|
Other Long-Term Assets | 3.94 | 3.86 | 3.72 | 3.8 | 3.77 | 14.31 | Upgrade
|
Total Assets | 358.5 | 274.95 | 146.39 | 207.01 | 279.24 | 284.25 | Upgrade
|
Accounts Payable | 12.78 | 12.84 | 16.92 | 7.28 | 13.8 | 9.07 | Upgrade
|
Accrued Expenses | 14.64 | 16.83 | 17.55 | 14.86 | 11.97 | 16.19 | Upgrade
|
Current Portion of Leases | 7.4 | 6.71 | 5.5 | 4.96 | 3.71 | 3.24 | Upgrade
|
Current Unearned Revenue | 135.91 | 150.06 | 31.56 | 37.1 | 91.56 | 89.65 | Upgrade
|
Total Current Liabilities | 170.73 | 186.44 | 71.52 | 64.2 | 121.04 | 118.15 | Upgrade
|
Long-Term Leases | 19.77 | 25.4 | 32.12 | 24.96 | 25.59 | 29.3 | Upgrade
|
Long-Term Unearned Revenue | 18.49 | 15.6 | 79.77 | 77.48 | 41.48 | 63.47 | Upgrade
|
Other Long-Term Liabilities | - | - | 0.19 | - | 0.47 | 1.72 | Upgrade
|
Total Liabilities | 208.99 | 227.45 | 183.6 | 166.64 | 188.59 | 212.64 | Upgrade
|
Common Stock | 1,140 | 935.37 | 802.83 | 749.85 | 694.09 | 539.55 | Upgrade
|
Additional Paid-In Capital | 153.2 | 129.24 | 119.44 | 87.98 | 71.57 | 57.28 | Upgrade
|
Retained Earnings | -1,151 | -1,025 | -967.34 | -805.51 | -683.27 | -533.36 | Upgrade
|
Comprehensive Income & Other | -0.16 | -0.12 | -0.03 | 0.18 | 0.39 | 0.27 | Upgrade
|
Total Common Equity | 141.64 | 39.63 | -45.09 | 32.5 | 82.78 | 63.73 | Upgrade
|
Shareholders' Equity | 149.51 | 47.5 | -37.22 | 40.37 | 90.65 | 71.61 | Upgrade
|
Total Liabilities & Equity | 358.5 | 274.95 | 146.39 | 207.01 | 279.24 | 284.25 | Upgrade
|
Total Debt | 27.17 | 32.12 | 37.61 | 29.92 | 29.31 | 32.55 | Upgrade
|
Net Cash (Debt) | 283.78 | 168.23 | 50.88 | 120.65 | 155.19 | 114.61 | Upgrade
|
Net Cash Growth | 167.02% | 230.63% | -57.83% | -22.26% | 35.40% | -34.44% | Upgrade
|
Net Cash Per Share | 2.26 | 1.59 | 0.65 | 2.33 | 3.96 | 3.38 | Upgrade
|
Filing Date Shares Outstanding | 152.52 | 122.28 | 98.1 | 60.84 | 49 | 34.54 | Upgrade
|
Total Common Shares Outstanding | 148.39 | 119.16 | 86.92 | 59.84 | 48.78 | 34.34 | Upgrade
|
Working Capital | 153.79 | 48.93 | 27.02 | 98.36 | 109 | 67.32 | Upgrade
|
Book Value Per Share | 0.95 | 0.33 | -0.52 | 0.54 | 1.70 | 1.86 | Upgrade
|
Tangible Book Value | 141.64 | 39.63 | -45.09 | 32.5 | 82.78 | 63.73 | Upgrade
|
Tangible Book Value Per Share | 0.95 | 0.33 | -0.52 | 0.54 | 1.70 | 1.86 | Upgrade
|
Machinery | - | 26.07 | 25.51 | 25.66 | 25.42 | 24.53 | Upgrade
|
Construction In Progress | - | 0.29 | 0.32 | 0.03 | 0.08 | 0.49 | Upgrade
|
Leasehold Improvements | - | 28.53 | 28.41 | 27.99 | 27.91 | 27.83 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.